Skip to main content
Loading

Neurocentrx

February 27, 2024
CNS/Neurological
Neurocentrx
Neurocentrx is seeking the 1st FDA approval of an abuse-deterrent oral ketamine therapy for depression suitable for clinical and home administration. The company is Phase 3 ready, with a patent abuse-deterrent capsule formulation that may be suitable for 505(b)(2) accelerated approval. The company is seeking $15M to fund Phase 2 proof-of-concept trials, which will demonstrate efficacy in treatment-resistant major depression, and a care pathway featuring clinically supervised bridging of treatment into home settings. The company works with leading psychiatrists at Kings College London and McLean / MGH hospitals. Once approved, our innovative oral ketamine care option can replace expensive and complex ketamine treatments currently used to treat severe depression. We have received investment from UK seed investors, the Scottish Enterprise Fund and the Wellcome Trust.
Testimonials

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP